Skip to content

Study · Observational study · 2017

6 results

Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.

Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, Yasu T, Harasawa H

Diabetes & metabolism23 Jun 2017Cited by 105 (Europe PMC)

PMID28648835 (opens in a new tab)DOI10.1016/j.diabet.2017.05.009 (opens in a new tab)PepBankPUB-28648835
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

AimThis study evaluated the effects of a glucagon-like peptide-1 receptor agonist on gastrointestinal (GI) tract motility and residue rates by examining GI transit time and lumen using capsule endoscopy.Material and methodsGI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).ResultsGastric transit time in the group with diabetic neuropathy (DN) was 1:12:36±1:04:30h before liraglutide administration and 0:48:40±0:32:52h after administration (nonsignificant difference, P=0.19). Gastric transit time in the non-DN group was 1:01:30±0:52:59h before administration and 2:33:29±1:37:24h after administration (significant increase, P=0.03). Duodenal and small intestine transit time in the DN group was 4:10:34±0:25:54h before and 6:38:42±3:52:42h after administration (not significant, P=0.09) and, in the non-DN group, 3:51:03±0:53:47h before and 6:45:31±2:41:36h after administration (significant increase, P=0.03). The GI residue rate in the DN group was 32.1±24% before administration and 90.0±9.1% after administration (significant increase, P<0.001), and increased in all patients; in the non-DN group, it was 32.1±35.3% before and 78.3±23.9% after administration (significant increase, P<0.001), and also increased in all patients.ConclusionLiraglutide causes delayed gastric emptying and inhibits duodenal and small intestine motility. However, these GI movement-inhibiting effects may be decreased or absent in patients with DN-associated dysautonomia.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyMechanism

    In patients with type 2 diabetes and diabetic neuropathy, gastric transit time on capsule endoscopy did not change significantly after liraglutide.

    In plain wordsIn people with type 2 diabetes and nerve damage, liraglutide did not clearly change how fast the stomach passed the capsule.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastric transit time, DN group
    Study

    n: not reported in source

    Comparator
    Before liraglutide administration
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastric transit time in the group with diabetic neuropathy (DN) was 1:12:36±1:04:30h before liraglutide administration and 0:48:40±0:32:52h after administration (nonsignificant difference, P=0.19).
    1 context sentence
    Summary · context
    GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).
  2. 02HumanObservational studyMechanism

    In patients with type 2 diabetes without diabetic neuropathy, gastric transit time on capsule endoscopy increased significantly after liraglutide.

    In plain wordsIn people with type 2 diabetes without nerve damage, gastric transit time was longer after liraglutide than before it.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastric transit time, non-DN group
    Study

    n: not reported in source

    Comparator
    Before liraglutide administration
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastric transit time in the non-DN group was 1:01:30±0:52:59h before administration and 2:33:29±1:37:24h after administration (significant increase, P=0.03).
    1 context sentence
    Summary · context
    GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).
  3. 03HumanObservational studyMechanism

    In patients with type 2 diabetes and diabetic neuropathy, duodenal and small intestine transit time did not change significantly after liraglutide.

    In plain wordsIn people with type 2 diabetes and nerve damage, liraglutide did not clearly change gut transit time in the small intestine.

    Peptide
    Liraglutide
    Outcome
    No significant changeDuodenal and small intestine transit time, DN group
    Study

    n: not reported in source

    Comparator
    Before liraglutide administration
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Duodenal and small intestine transit time in the DN group was 4:10:34±0:25:54h before and 6:38:42±3:52:42h after administration (not significant, P=0.09)
    1 context sentence
    Summary · context
    GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).
  4. 04HumanObservational studyMechanism

    In patients with type 2 diabetes without diabetic neuropathy, duodenal and small intestine transit time increased significantly after liraglutide.

    In plain wordsIn people with type 2 diabetes without nerve damage, transit time through the small intestine was longer after liraglutide than before it.

    Peptide
    Liraglutide
    Outcome
    IncreaseDuodenal and small intestine transit time, non-DN group
    Study

    n: not reported in source

    Comparator
    Before liraglutide administration
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in the non-DN group, 3:51:03±0:53:47h before and 6:45:31±2:41:36h after administration (significant increase, P=0.03).
    1 context sentence
    Summary · context
    GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).
  5. 05HumanObservational studyMechanism

    In patients with type 2 diabetes and diabetic neuropathy, the gastrointestinal residue rate increased significantly after liraglutide (32.1% to 90.0%).

    In plain wordsIn people with type 2 diabetes and nerve damage, more residue was left in the gut after liraglutide than before it.

    Peptide
    Liraglutide
    Outcome
    IncreaseGI residue rate, DN group
    Study

    n: not reported in source

    Comparator
    Before liraglutide administration
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    GI residue rate before
    32.1%
    DN group
    GI residue rate after
    90%
    DN group

    Source sentences

    Summary
    The GI residue rate in the DN group was 32.1±24% before administration and 90.0±9.1% after administration (significant increase, P<0.001)
    1 context sentence
    Summary · context
    GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).
  6. 06HumanObservational studyMechanism

    In patients with type 2 diabetes without diabetic neuropathy, the gastrointestinal residue rate increased significantly after liraglutide (32.1% to 78.3%).

    In plain wordsIn people with type 2 diabetes without nerve damage, more residue was left in the gut after liraglutide than before it.

    Peptide
    Liraglutide
    Outcome
    IncreaseGI residue rate, non-DN group
    Study

    n: not reported in source

    Comparator
    Before liraglutide administration
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    GI residue rate before
    32.1%
    non-DN group
    GI residue rate after
    78.3%
    non-DN group

    Source sentences

    Summary
    in the non-DN group, it was 32.1±35.3% before and 78.3±23.9% after administration (significant increase, P<0.001), and also increased in all patients.
    1 context sentence
    Summary · context
    GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07756359

Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

University of North Carolina, Chapel Hilln = 20est. Sept 2026 to est. Sept 2027

Pouch, Ileal · Pouches, Ileoanal · Bowel Diseases, Inflammatory

Trial pageClinicalTrials.govUpdated 10 Aug 2026
Status unknownPhase 4NCT04046822

Effect of Liraglutide on Microbiome in Obesity

Federico II Universityn = 709 Jan 2019 to est. 30 Apr 2020

Obesity · Weight Loss · Microbiome

Trial pageClinicalTrials.govUpdated 20 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.